IP Library › Granted Patent US 12,427,171
Granted Patent B2
US 12,427,171 · App. 18/226,395 · Granted Sep 30, 2025

Krill oil composition enriched in LPC-DHA and LPC-EPA

Inventors: Finn Myhren (Stamsund, NO); Petter-Arnt Hals (Stamsund, NO); Nils Hoem (Stamsund, NO); Andreas Berg Storsve (Stamsund, NO); Papasani V. Subbaiah (Darien, IL); Poorna Yalagala (Urbana, IL); Sugasini Dhavamani (Urbana, IL); Leon Tai (Urbana, IL)
Assignees: Aker BioMarine Human Ingredients AS; The Board of Trustees of the University of Illinois
A61K35/612A61K9/0019A61K9/0053A61K31/047A61K31/122A61K31/685A61P27/02C12P9/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,427,171
App. No.
18/226,395
Granted
Sep 30, 2025
Kind
B2
Abstract

The present invention provides compositions comprising phosphatidylcholine derived compounds carrying an omega-3 fatty acid for use in prophylaxis or therapy, particularly when administered systemically. This invention further relates to a modified krill oil composition enriched in LPC-DHA and LPC-EPA, methods of making and methods of using to treat neurological and ocular disorders.

Claims (32)

1. A method for treating a liver disease selected from the group consisting of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a subject in need thereof comprising:

administering to the subject in need thereof an effective amount of a pharmaceutical or nutraceutical formulation comprising a lysophosphatidylcholine (LPC) composition comprising a LPC-compound selected from the group consisting of any one of formulas 1 to 8, and any combination thereof, so that the symptoms of the disease or condition are improved, controlled, reduced, or alleviated:

wherein:

R 1 is OH or —OC(O)(CH 2 ) n CH 3 ;

R 2 is OH or —OC(O)(CH 2 ) n CH 3 ; and

n is 0, 1, or 2;

and wherein the molar ratio of lysoPC-DHA:lysoPC-EPA is in the range of from 3:1 to 1:5; and

further wherein

i) the number of moles of lysoPC-EPA is the number of moles 1-lysoPC-EPA plus the number of moles 2-lysoPC-EPA; and

ii) ii) the number of moles of lysoPC-DHA is the number of moles 1-lysoPC-DHA plus the number of moles 2-lysoPC-DHA.

2. The method of claim 1 , wherein R 1 is OH and R 2 is OH.

3. The method according to claim 1 , with the proviso that: if the LPC composition comprises i) a compound according to formula 1, wherein R 2 is OH; and/or ii) a compound according to formula 3, wherein R 1 is OH; then the LPC composition further comprises at least one of the other LPC-compounds referred to in claim 1 .

4. The method of claim 1 , wherein the one or more LPC-compound is:

a compound according to formula 1; and/or a compound according to formula 3; and

a compound according to formula 2; and/or a compound according to formula 4.

5. The method of claim 1 , wherein

R 1 and R 2 are OH; and

the molar ratio of lysoPC-DHA:lysoPC-EPA is from 1:1 to 3:1 wherein i) the number of moles of lysoPC-EPA is the number of moles 1-lysoPC-EPA+the number of moles 2-lysoPC-EPA; and ii) the number of moles of lysoPC-DHA is the number of moles 1-lysoPC-DHA+the number of moles 2-lysoPC-DHA.

6. The method of claim 1 , wherein the disease is non-alcoholic fatty liver disease.

7. The method of claim 1 , wherein the disease is non-alcoholic steatohepatitis.

8. The method of claim 1 , wherein the administering is by a mode selected from the group consisting of oral administration and intravascular administration.

9. The method of claim 8 , wherein the mode of administration is oral administration.

10. The method of claim 8 , wherein the mode of administration is intravascular administration.

11. The method of claim 1 , wherein the LPC composition in the formulation comprises an amount of total LPC from 10% to 100% by weight of the LPC composition.

12. The method of claim 1 , wherein the LPC composition comprises an additional lipid different from LPC.

13. The method of claim 12 , wherein the additional lipid is selected from the group consisting of triglycerides, free fatty acids, ethyl esters and phospholipids selected from the group consisting of phosphatidylethanolamine and phosphatidylcholine.

14. The method of claim 13 , wherein the LPC composition comprises a predominant amount of the LPC-compound compared to an amount of phosphatidylcholine.

15. The method of claim 1 , wherein the subject is a mammalian subject.

16. The method of claim 15 , wherein the subject is a human subject.

17. The method of claim 1 , wherein:

R 1 and R 2 are OH; and

the molar ratio of lysoPC-DHA:lysoPC-EPA is 3:1 to 1:5; wherein i) the number of moles of lysoPC-EPA is the number of moles 1-lysoPC-EPA+the number of moles 2-lysoPC-EPA; and ii) the number of moles of lysoPC-DHA is the number of moles 1-lysoPC-DHA+the number of moles 2-lysoPC-DHA.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2024
From: AKER BIOMARINE ANTARCTIC AS
To: AKER BIOMARINE HUMAN INGREDIENTS AS
Reel/Frame 066703/0864 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2023
From: MYHREN, FINN; HALS, PETTER-ARNT; STORSVE, ANDREAS BERG; HOEM, NILS
To: AKER BIOMARINE ANTARCTIC AS
Reel/Frame 065444/0551 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2023
From: SUBBAIAH, PAPASANI V.; YALAGALA, POORNA; DHAVAMANI, SUGASINI; TAI, LEON
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Reel/Frame 065444/0647 →
Continuity (4)
Continuation 17218760 · Mar 31, 2021
Provisional Application 63113908 · Nov 15, 2020
Provisional Application 63002425 · Mar 31, 2020
Related Publication 20230364157A1 · Nov 16, 2023
References Cited (101)
US 20180325924A1 · Subbaiah · 2018 [cited by examiner]
WO WO2008068413 · 2008 [cited by applicant]
WO WO2015048554 · 2015 [cited by applicant]
WO WO2018162617 · 2018 [cited by applicant]
WO WO2019123015 · 2019 [cited by applicant]
WO WO2020254675 · 2020 [cited by applicant]
Abcouwer S.F., Gardner T.W. Diabetic retinopathy: Loss of neuroretinal adaptation to the diabetic metabolic environment. [cited by applicant]
Anderson R.E., Maude M.B., Bok D. Low docosahexaenoic acid levels in rod outer segment membranes of mice with rds/peripherin and P216L peripherin mutations. [cited by applicant]
Arsenault, D., Julien, C., Tremblay, C., and Calon, F. (2011) DHA Improves Cognition and Prevents Dysfunction of Entorhinal Cortex Neurons in 3xTg-AD Mice. PLoS One 6, e17397. [cited by applicant]
Balakrishnan, J. et al., Structured form of DHA prevents neurodegenerative disorders: A better insight into the pathophysiology and the mechanism of DHA transport to the brain. [cited by applicant]
Barrett, E. C., McBurney, M. I., and Ciappio, E. D. (2014) Omega-3 Fatty Acid Supplementation as a Potential Therapeutic Aid for the Recovery from Mild Traumatic Brain Injury/Concussion. [cited by applicant]
Bazan, N. G. (2018) Docosanoids and elovanoids from omega-3 fatty acids are pro-homeostatic modulators of inflammatory responses, cell damage and neuroprotection. [cited by applicant]
Bazan, N. G., Molina, M. F., and Gordon, W. C. (2011) Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative disease… [cited by applicant]
Bernice H. Wong et al: “Mfsd2a Is a Transporter for the Essential [omega]-3 Fatty Acid Docosahexaenoic Acid (DHA) in Eye and Is Important for Photoreceptor Cell Development”, Journal of Biological Chemistry, vol. 291, N… [cited by applicant]
Bligh, E. G., and Dyer, W. J. (1959) A rapid method of total lipid extraction and purification. [cited by applicant]
Brindley, D. N. (1993) Hepatic secretion of lysophosphatidylcholine: A novel transport system for polyunsaturated fatty acids and choline. [cited by applicant]
Chen, A. T., Chibnall, J. T., and Nasrallah, H. A. (2015) A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects. [cited by applicant]
Chen, C. T., and Bazinet, R. P. (2015) b-oxidation and rapid metabolism, but not uptake regulate brain eicosapentaenoic acid levels. [cited by applicant]
Chew, E. Y., Clemons, T. E., Agrón, E., Launer, L. J., Grodstein, F., Bernstein, P. S., and Group, f. t. A.-R. E. D. S. R. (2015) Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Co… [cited by applicant]
Chiu, C. C., Su, K. P., Cheng, T. C., Liu, H. C., Chang, C. J., Dewey, M. E., Stewart, R., and Huang, S. Y. (2008) The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A p… [cited by applicant]
Connor K.M., SanGiovanni J.P., Lofqvist C., Aderman C.M., Chen J., Higuchi A., Hong S., Pravda E.A., Majchrzak S., Carper D., et al. Increased dietary intake of -ë-3-polyunsaturated fatty acids reduces pathological reti… [cited by applicant]
Croset, M., Brossard, N., Polette, A., and Lagarde, M. (2000) Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochemical Journal 345, 61-67. [cited by applicant]
Cruz-Hernandez, C., Thakkar, S. K., Moulin, J., Oliveira, M., Masserey-Elmelegy, I., Dionisi, F., and Destaillats, F. (2012) Benefits of structured and free monoacylglycerols to deliver eicosapentaenoic (EPA) in a model… [cited by applicant]
Cunnane, S. C., Chouinard-Watkins, R., Castellano, C. A., and Barberger-Gateau, P. (2013) Docosahexaenoic acid homeostasis, brain aging and Alzheimer's disease: Can we reconcile the evidence? [cited by applicant]
Deinema et al. “A Randomized, Double-Masked, Pacebo-Controlled Clinical Trial of Two Forms of Moega-3 Supplements for Treating Dry Eye Disease” Ophthalmology. Jan. 2017;124(1):43-52. [cited by applicant]
Faiq M.A., Wollstein G., Schuman U.S., Chan K.C. Cholinergic nervous system and glaucoma: From basic science to clinical applications. [cited by applicant]
Ferreira, J. J., Rosser, A., Craufurd, D., Squitieri, F., Mallard, N., and Landwehrmeyer, B. (2015) Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial. [cited by applicant]
Futterman S., Sturtevant R., Kupfer C. Effect of alloxan diabetes on the fatty acid composition of the retina. [cited by applicant]
Gong J., Rosner B., Rees D.G., Berson E.L., Weigel-DiFranco C.A., Schaefer E.J. Plasma docosahexaenoic acid levels in various genetic forms of retinitis pigmentosa. [cited by applicant]
Green P., Glozman S., Weiner L., Yavin E. Enhanced free radical scavenging and decreased lipid peroxidation in the rat fetal brain after treatment with ethyl docosahexaenoate. [cited by applicant]
Hachem M., Geloen A., Van A., Foumaux B., Fenart L., Gosselet F., Da Silva P., Breton G., Lagarde M., Picq M., et al. Efficient docosahexaenoic acid uptake by the brain from a structured phospholipid. [cited by applicant]
Harauma, A., Saito, J., Watanabe, Y., and Moriguchi, T. (2014) Potential for daily supplementation of n-3 fatty acids to reverse symptoms of dry eye in mice. [cited by applicant]
Hashimoto M., Hossain S., Al Mamun A., Matsuzaki K., Arai H. Docosahexaenoic acid: One molecule diverse functions. Crit. Rev. Biotechnol. 2017;37:579-597. doi: 10.1080/07388551.2016.1207153. [cited by applicant]
Hegde K.R., Varma S.D. Electron impact mass spectroscopic studies on mouse retinal fatty acids: Effect of diabetes. [cited by applicant]
Hoffman D.R., Hughbanks-Wheaton D.K., Pearson N.S., Fish G.E., Spencer R., Takacs A., Klein M., Locke K.G., Birch D.G. Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX tr… [cited by applicant]
Hong, S. H., Belayev, L., Khoutorova, L., Obenaus, A., and Bazan, N. G. (2014) Docosahexaenoic acid confers enduring neuroprotection in experimental stroke. J Neurol. Sci 338, 135-141. [cited by applicant]
International Search Report & Written Opinion based on PCT/US2021/025110; mailed Dec. 23, 2021; 26 pages. [cited by applicant]
Ivanova, P. T., Milne, S. B., Byrne, M. O., Xiang, Y., and Brown, H. A. (2007) Glycerophospholipid identification and quantitation by electrospray ionization mass spectrometry. [cited by applicant]
Jasani B., Simmer K., Patole S.K., Rao S.C. Long chain polyunsaturated fatty acid supplementation in infants born at term. [cited by applicant]
Jump, D. B., Depner, C. M., Tripathy, S., and Lytle, K. A. (2015) Potential for Dietary ω-3 Fatty Acids to Prevent Nonalcoholic Fatty Liver Disease and Reduce the Risk of Primary Liver Cancer. [cited by applicant]
Jun B., Mukherjee P.K., Asatryan A., Kautzmann M.A., Heap J., Gordon W.C., Bhattacharjee S., Yang R., Petasis N.A., Bazan N.G. Elovanoids are novel cell-specific lipid mediators necessary for neuroprotective signaling f… [cited by applicant]
Kalogerou M., Kolovos P., Prokopiou E., Papagregoriou G., Deltas C., Malas S., Georgiou T. Omega-3 fatty acids protect retinal neurons in the DBA/2J hereditary glaucoma mouse model. [cited by applicant]
Kaur G., Molero J.C., Weisinger H.S., Sinclair A.J. Orally administered [14C] DPA and [14C] DHA are metabolised differently to [14C] EPA in rats. [cited by applicant]
Kaur, G., Begg, D. P., Barr, D., Garg, M., Cameron-Smith, D., and Sinclair, A. J. (2010) Short-term docosapentaenoic acid (22:5 n-3) supplementation increases tissue docosapentaenoic acid, DHA and EPA concentrations in … [cited by applicant]
Kelley, N. S. (2016) Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans. [cited by applicant]
Lee, T. K. M., Clandinin, M. T., Hébert, M., and MacDonald, I. M. (2010) Effect of docosahexaenoic acid supplementation on the macular function of patients with Best vitelliform macular dystrophy: randomized clinical tr… [cited by applicant]
Lim, S. Y., and Suzuki, H. (2001) Changes in Maze Behavior of Mice Occur after Sufficient Accumulation of Docosahexaenoic Acid in Brain. [cited by applicant]
Lima Giacobbo, B., Doorduin, J., Klein, H. C., Dierckx, R. A. J. O., Bromberg, E., and de Vries, E. F. J. (2019) Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation. [cited by applicant]
Lobanova E.S., Schuhmann K., Finkelstein S., Lewis T.R., Cady M.A., Hao Y., Keuthan C., Ash J.D., Burns M.E., Shevchenko A., et al. Disrupted blood-retina lysophosphatidylcholine transport impairs photoreceptor health b… [cited by applicant]
Martínez M. Severe deficiency of docosahexaenoic acid in peroxisomal disorders: A defect of delta 4 desaturation? [cited by applicant]
Martins, J. G. (2009) EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled tri… [cited by applicant]
McCusker M.M., Durrani K., Payette M.J., Suchecki J. An eye on nutrition: The role of vitamins, essential fatty acids, and antioxidants in age-related macular degeneration, dry eye syndrome, and cataract. [cited by applicant]
Nair A.B., Jacob S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 2016;7:27-31. doi: 10.4103/0976-0105.177703. [cited by applicant]
Nguyen, L. N., Ma, D., Shui, G., Wong, P., Cazenave-Gassiot, A., Zhang, X., Wenk, M. R., Goh, E. L. K., and Silver, D. L. (2014) Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. [cited by applicant]
Nishizawa, Wang, Sekine, and Saito. (2003) Effect of Dietary DHA on DHA Levels in Retinal Rod Outer Segments in Young versus Mature Rats. [cited by applicant]
P. Heinrich Stahl, Camille G. Wermuth (Eds.), Handbook of pharmaceutical salts properties, Selection, and Use; 2002. [cited by applicant]
Perez, S. E., Berg, B. M., Moore, K. A., He, B., Counts, S. E., Fritz, J. J., Hu, Y. S., Lazarov, O., Lah, J. J., and Mufson, E. J. (2010) DHA diet reduces AD pathology in young APPswe/PS1delta E9 transgenic mice: Possi… [cited by applicant]
Petursdottir, A. L., Farr, S. A., Morley, J. E., Banks, W. A., and Skuladottir, G. V. (2008) Effect of Dietary n-3 Polyunsaturated Fatty Acids on Brain Lipid Fatty Acid Composition, Learning Ability, and Memory of Senes… [cited by applicant]
Phillips, M. A., Childs, C. E., Calder, P. C., and Rogers, P. J. (2015) No. Effect of Omega-3 Fatty Acid Supplementation on Cognition and Mood in Individuals with Cognitive Impairment and Probable Alzheimer's Disease: A… [cited by applicant]
Prokopiou E., Kolovos P., Georgiou C., Kalogerou M., Potamiti L., Sokratous K., Kyriacou K., Georgiou T. Omega-3 fatty acids supplementation protects the retina from age-associated degeneration in aged C57BL/6J mice. [cited by applicant]
Prokopiou E., Kolovos P., Kalogerou M., Neokleous A., Nicolaou O., Sokratous K., Kyriacou K., Georgiou T. Omega-3 fatty acids supplementation: Therapeutic potential in a mouse model of stargardt disease. [cited by applicant]
Qiu, S., Wei, Y., Zhou, X., Jiang, Z., Zhang, T., Jiang, X., and Zhang, S. (2017) Intravitreal injection of docosahexaenoic acid attenuated photoreceptor cell injury in a NalO3-induced age-related macular degeneration r… [cited by applicant]
Querques, G., Forte, R. and Souied, E.H. (2011) Retina and Omega-3. [cited by applicant]
Quinn, J. F., Raman, R., and Thomas, R. G. (2010) Docosahexaenoic acid supplementation and cognitive decline in alzheimer disease: A randomized trial. [cited by applicant]
Ramprasath, V. R., Eyal, I., Zchut, S., and Jones, P. J. H. (2013) Enhanced increase of omega-3 index in healthy individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil. [cited by applicant]
Rodrigues, P. O., Martins, S. V., Lopes, P. A., Miguueis, S., Alfaia, C. M., Pinto, R. M. A., Rolo, E. A., Bispo, P., Batista, I., Bandarra, N. M., and Prates, J. A. M. (2014) Influence of feeding graded levels of canne… [cited by applicant]
Ross, B. M. (2008) The Emerging Role of Eicosapentaenoic Acid as an Important Psychoactive Natural Product: Some Answers but a Lot more Questions. [cited by applicant]
Rossino M.G., Casini G. Nutraceuticals for the treatment of diabetic retinopathy. Nutrients. 2019;11:771. doi: 10.3390/nu11040771. [cited by applicant]
Salem, N., and Kuratko, C. N. (2014) A reexamination of krill oil bioavailability studies. [cited by applicant]
SanGiovanni J.P., Chew E.Y. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. [cited by applicant]
Sapieha P., Chen J., Stahl A., Seaward M.R., Favazza T.L., Juan A.M., Hatton C.J., Joyal U.S., Krah N.M., Dennison R.J., et al. Omega-3 polyunsaturated fatty acids preserve retinal function in type 2 diabetic mice. [cited by applicant]
Schaefer E.J., Robins S.J., Patton G.M., Sandberg M.A., Weigel-DiFranco C.A., Rosner B., Berson E.L. Red blood cell membrane phosphatidylethanolamine fatty acid content in various forms of retinitis pigmentosa. [cited by applicant]
Schnebelen C., Viau S., Grégoire S., Joffre C., Creuzot-Garcher C.P., Bron A.M., Bretillon L., Acar N. Nutrition for the eye: Different susceptibility of the retina and the lacrimal gland to dietary omega-6 and omega-3 … [cited by applicant]
Schuchardt, J. P., Schneider, I., Meyer, H., Neubronner, J., von Schacky, C., and Hahn, A. (2011) Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations—a compara… [cited by applicant]
Sekas, G., Patton, G. M., Lincoln, E. C., and Robins, S. J. (1985) Origin of plasma lysophosphatidylcholine: evidence for direct hepatic secretion in the rat. [cited by applicant]
Sethom, M. M., Fares, S., Bouaziz, N., Melki, W., Jemaa, R., Feki, M., Hechmi, Z., and Kaabachi, N. (2010) Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with … [cited by applicant]
Sona, C., Kumar, A., Dogra, S., Kumar, B. A., Umrao, D., and Yadav, P. N. (2018) Docosahexaenoic acid modulates brain-derived neurotrophic factor via GPR40 in the brain and alleviates diabesity-associated learning and m… [cited by applicant]
Song, C., Shieh, C. H., Wu, Y. S., Kalueff, A., Gaikwad, S., and Su, K. P. (2016) The role of omega-3 polyunsaturated fatty acids eicosapentaenoic and docosahexaenoic acids in the treatment of major depression and Alzhe… [cited by applicant]
Souied, E. H., Aslam, T., Garcia-Layana, A., Holz, F. G., Leys, A., Silva, R., and Delcourt, C. (2016) Omega-3 Fatty Acids and Age-Related Macular Degeneration. [cited by applicant]
Stinson A.M., Wiegand R.D., Anderson R.E. Recycling of docosahexaenoic acid in rat retinas during n-3 fatty acid deficiency. [cited by applicant]
Subbaiah, P. V., Dammanahalli, K. J., Yang, P., Bi, J., and O'Donnell, J. M. (2016) Enhanced incorporation of dietary DHA into lymph phospholipids by altering its molecular carrier. [cited by applicant]
Sugasini D et al. Efficient enrichment of retinal DHA with dietary lysophosphatidylcholine-DHA: potential application for retinopathies; [cited by applicant]
Sugasini, D., and Subbaiah, P. V. (2017) Rate of acyl migration in lysophosphatidylcholine (LPC) is dependent upon the nature of the acyl group. Greater stability of sn-2 docosahexaenoyl LPC compared to the more saturat… [cited by applicant]
Sugasini, D., Thomas, R., Yalagala, P. C. R., Tai, L. M., and Subbaiah, P. V. (2017) Dietary docosahexaenoic acid (DHA) as lysophosphatidylcholine, but not as free acid, enriches brain DHA and improves memory in adult m… [cited by applicant]
Sugasini, D., Yalagala, P. C. R., Goggin, A., Tai, L. M., and Subbaiah, P. V. (2019) Enrichment of brain docosahexaenoic acid (DHA) is highly dependent upon the molecular carrier of dietary DHA: Lysophosphatidylcholine … [cited by applicant]
Suh M., Clandinin M.T. 20:5n-3 but not 22:6n-3 is a preferred substrate for synthesis of n-3 very-long-chain fatty acids (C24-C36) in retina. [cited by applicant]
Suh M., Sauvé Y., Merrells K.J., Kang J.X., Ma D.W.L. Supranormal electroretinogram in F at-1 mice with retinas enriched in docosahexaenoic acid and n-3 very long chain fatty acids (C24-C36) Investig. Ophtalmol. Vis. Sc… [cited by applicant]
Sun, G. Y., Simonyi, A., Fritsche, K. L., Chuang, D. Y., Hannink, M., Gu, Z., Greenlief, C. M., Yao, J. K., Lee, J. C., and Beversdorf, D. Q. (2018) Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical … [cited by applicant]
Tachikawa M., Akanuma S.I., Imai T., Okayasu S., Tomohiro T., Hatanaka Y., Hosoya K.I. Multiple cellular transport and binding processes of unesterified docosahexaenoic acid in outer blood-retinal barrier retinal pigmen… [cited by applicant]
Tanito M., Brush R.S., Elliott M.H., Wicker L.D., Henry K.R., Anderson R.E. High levels of retinal membrane docosahexaenoic acid increase susceptibility to stress-induced degeneration. [cited by applicant]
Thies F., Delachambre M.C., Bentejac M., Lagarde M., Lecerf J. Lyso-sn 1 Phosphatidylcholine Bound to Albumin: A Preferential Form for Rat Brain Uptake of Unsaturated Fatty Acids Compared to the Unesterified Form?; Proc… [cited by applicant]
Tikhonenko, M., Lydic, T. A., Opreanu, M., Li Calzi, S., Bozack, S., McSorley, K. M., Sochacki, A. L., Faber, M. S., Hazra, S., Duclos, S., Guberski, D., Reid, G. E., Grant, M. B., and Busik, J. V. (2013) N-3 Polyunsatu… [cited by applicant]
Tou, J., Altman, S., Gigliotti, J., Benedito, V., and Cordonier, E. (2011) Different sources of omega-3 polyunsaturated fatty acids affects apparent digestibility, tissue deposition, and tissue oxidative stability in gr… [cited by applicant]
Uauy R., Hoffman D.R., Peirano P., Birch D.G., Birch E.E. Essential fatty acids in visual and brain development. [cited by applicant]
Valenzuela A. et al. Supplementing female rates with DHA-lysophosphatidylcholine increases docosahexaenoic acid and acetylcholine contents in the brain and improves the memory and learning capabilities of the pups. [cited by applicant]
Wong B.H., Chan J.P., Cazenave-Gassiot A., Poh R.W., Foo J.C., Galam D.L., Ghosh S., Nguyen L.N., Barathi V.A., Yeo S.W., et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid (DHA) in… [cited by applicant]
Yalagala P.C.R., Sugasini D., Zaldua S.B., Tai L.M., Subbaiah P.V. Lipase treatment of dietary krill oil, but not fish oil, enables enrichment of brain eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [cited by applicant]
Yalagala, P. C. R., Sugasini, D., Dasarathi, S., Pahan, K., and Subbaiah, P. V. (2019) Dietary lysophosphatidylcholine-EPA enriches both EPA and DHA in the brain: potential treatment for depression. [cited by applicant]
Yang S.P., Morita I., Murota S.I. Eicosapentaenoic acid attenuates vascular endothelial growth factor-induced proliferation via inhibiting Flk-1 receptor expression in bovine carotid artery endothelial cells. [cited by applicant]
Yee P., Weymouth A.E., Fletcher E.L., Vingrys A.J. A Role for Omega-3 Polyunsaturated Fatty Acid Supplements in Diabetic Neuropathy. [cited by applicant]
Yu M., Benham A., Logan S., Brush R.S., Mandal M.N., Anderson R.E., Agbaga M.P. ELOVL4 protein preferentially elongates 20:5n3 to very long chain PUFAs over 20:4n6 and 22:6n3. [cited by applicant]